Compare WGO & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | BHVN |
|---|---|---|
| Founded | 1958 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2017 |
| Metric | WGO | BHVN |
|---|---|---|
| Price | $43.73 | $11.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 15 |
| Target Price | ★ $43.00 | $29.43 |
| AVG Volume (30 Days) | 709.2K | ★ 3.4M |
| Earning Date | 12-19-2025 | 11-10-2025 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $2,875,300,000.00 | N/A |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $5.20 | $1,147.70 |
| P/E Ratio | $33.17 | ★ N/A |
| Revenue Growth | ★ 1.38 | N/A |
| 52 Week Low | $28.00 | $7.48 |
| 52 Week High | $50.31 | $44.28 |
| Indicator | WGO | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 63.07 | 54.16 |
| Support Level | $39.33 | $9.32 |
| Resistance Level | $43.38 | $12.05 |
| Average True Range (ATR) | 1.91 | 1.02 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 48.70 | 84.23 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.